Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2020 WS
-
2020 SS
-
2019 WS
-
2019 SS
-
2018 WS
-
2017 WS
-
2017 SS
-
2016 WS
-
2016 SS
-
2015 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 200 (2024) 113536Online Volltext: dx.doi.org/ (Open Access)
-
Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanomaIn: Nature Communications Jg. 15 (2024) Nr. 1, 524Online Volltext: dx.doi.org/ (Open Access)
-
Federated Learning for Decentralized Artificial Intelligence in Melanoma DiagnosticsIn: JAMA Dermatology Jg. 160 (2024) Nr. 3, S. 303 - 311Online Volltext: dx.doi.org/ (Open Access)
-
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma : A multicenter study on 1383 patients of the prospective DeCOG registry ADORegIn: International Journal of Cancer Jg. 155 (2024) Nr. 10, S. 1808 - 1823Online Volltext: dx.doi.org/ (Open Access)
-
Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface densityIn: Molecular Oncology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity : a multicenter case seriesIn: Journal for ImmunoTherapy of Cancer Jg. 12 (2024) Nr. 1, e008232Online Volltext: dx.doi.org/ (Open Access)
-
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient careIn: Communications Medicine Jg. 4 (2024) Nr. 1, 177Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O) : disease-free survival results from a randomised, open-label, phase 2 trialIn: Lancet Jg. 402 (2023) Nr. 10404, S. 798 - 808Online Volltext: dx.doi.org/
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC) Jg. 191 (2023) 112957Online Volltext: dx.doi.org/
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4,Online Volltext: dx.doi.org/ (Open Access)
-
Clinical, histopathological and molecular features of dedifferentiated melanomas : An EORTC Melanoma Group Retrospective AnalysisIn: European Journal of Cancer (EJC) Jg. 187 (2023) S. 7 - 14Online Volltext: dx.doi.org/
-
Tebentafusp in Patients with Metastatic Uveal Melanoma : A Real-Life Retrospective Multicenter StudyIn: Cancers Jg. 15 (2023) Nr. 13, 3430Online Volltext: dx.doi.org/ (Open Access)
-
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : A multicenter study from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 9, e007630Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet Jg. 400 (2022) Nr. 10358, S. 1117 - 1129Online Volltext: dx.doi.org/
-
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced MelanomaIn: Cancers Jg. 14 (2022) Nr. 9, 2294Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy”In: European Journal of Cancer (EJC) Jg. 162 (2022) S. 245 - 246Online Volltext: dx.doi.org/
-
Explainable artificial intelligence in skin cancer recognition : A systematic reviewIn: European Journal of Cancer (EJC) Jg. 167 (2022) S. 54 - 69Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72Online Volltext: dx.doi.org/
-
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma : A multicenter study of the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 11, e005930Online Volltext: dx.doi.org/ (Open Access)
-
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma : An evaluation of the multicenter prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 167 (2022) S. 32 - 41Online Volltext: dx.doi.org/ (Open Access)
-
Model soups improve performance of dermoscopic skin cancer classifiersIn: European Journal of Cancer (EJC) Jg. 173 (2022) S. 307 - 316Online Volltext: dx.doi.org/ (Open Access)
-
A benchmark for neural network robustness in skin cancer classificationIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 191 - 199Online Volltext: dx.doi.org/ (Open Access)
-
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaIn: Cancer Immunology, Immunotherapy Jg. 70 (2021) Nr. 7, S. 2087 - 2093Online Volltext: dx.doi.org/ (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154Online Volltext: dx.doi.org/
-
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classificationIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 94 - 101Online Volltext: dx.doi.org/ (Open Access)
-
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Jg. 118 (2021) Nr. 43, e2102849118Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers Jg. 13 (2021) Nr. 10, S. 2319Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Integrating patient data into skin cancer classification using convolutional neural networks : Systematic reviewIn: Journal of Medical Internet Research (JMIR) Jg. 23 (2021) Nr. 7, e20708Online Volltext: dx.doi.org/ (Open Access)
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 61 - 75Online Volltext: dx.doi.org/
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 6, S. 1763 - 1771Online Volltext: dx.doi.org/ (Open Access)
-
Robustness of convolutional neural networks in recognition of pigmented skin lesionsIn: European Journal of Cancer (EJC) Jg. 145 (2021) S. 81 - 91Online Volltext: dx.doi.org/ (Open Access)
-
Skin cancer classification via convolutional neural networks : Systematic review of studies involving human expertsIn: European Journal of Cancer (EJC) Jg. 156 (2021) S. 202 - 216Online Volltext: dx.doi.org/ (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45Online Volltext: dx.doi.org/
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568Online Volltext: dx.doi.org/
-
Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification : Web-Based Survey StudyIn: Journal of Medical Internet Research (JMIR) Jg. 22 (2020) Nr. 9, S. e18091Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147Online Volltext: dx.doi.org/ (Open Access)
-
Conceptual framework for precision cancer medicine in Germany : Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’In: European Journal of Cancer (EJC) Jg. 135 (2020) S. 1 - 7Online Volltext: dx.doi.org/
-
Effects of Label Noise on Deep Learning-Based Skin Cancer ClassificationIn: Frontiers in Medicine Jg. 7 (2020) S. 177Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939Online Volltext: dx.doi.org/ (Open Access)
-
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics Jg. 52 (2020) Nr. 12, S. 1373 - 1383Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Localization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticlesIn: Journal of Biophotonics Jg. 13 (2020) Nr. 3, e201960034Online Volltext: dx.doi.org/ (Open Access)
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 148 - 154Online Volltext: dx.doi.org/ (Open Access)
-
Chemoirradiated neutrophils and T cells differentially affect immune functions of APCsIn: Journal of Leukocyte Biology (JLB) Jg. 106 (2019) Nr. 2: Special Focus Issue: Tissue Phagocyte Heterogeneity in Health and Disease (AAI/SLB), S. 481 - 493Online Volltext: dx.doi.org/
-
Comparing artificial intelligence algorithms to 157 German dermatologists : the melanoma classification benchmarkIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 30 - 37Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 113 (2019) S. 47 - 54Online Volltext: dx.doi.org/ (Open Access)
-
Deep neural networks are superior to dermatologists in melanoma image classificationIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 11 - 17Online Volltext: dx.doi.org/ (Open Access)
-
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 2515 - 2515Online Volltext: dx.doi.org/
-
Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaIn: European Journal of Cancer (EJC) Jg. 116 (2019) S. 207 - 215Online Volltext: dx.doi.org/
-
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 5, S. 765 - 772Online Volltext: dx.doi.org/
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927Online Volltext: dx.doi.org/ (Open Access)
-
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence : A call for prospective dataIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 30 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Superior skin cancer classification by the combination of human and artificial intelligenceIn: European Journal of Cancer (EJC) Jg. 120 (2019) S. 114 - 121Online Volltext: dx.doi.org/ (Open Access)
-
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 57 - 65Online Volltext: dx.doi.org/ (Open Access)
-
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 33, S. 3142 - 3151Online Volltext: dx.doi.org/ (Open Access)
-
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell Jg. 175 (2018) Nr. 4, S. 984 - 997.e24Online Volltext: dx.doi.org/ (Open Access)
-
Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-Cell populationsIn: Clinical Cancer Research Jg. 24 (2018) Nr. 21, S. 5347 - 5356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Can checkpoint inhibitor therapy improve response to chemotherapy?In: Journal of Cancer Research and Clinical Oncology Jg. 144 (2018) Nr. 1, S. 183 - 185Online Volltext: dx.doi.org/
-
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell Jg. 173 (2018) Nr. 3, S. 624 - 633.e8Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology Jg. 7 (2018) Nr. 8, e1450127Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics Jg. 50 (2018) Nr. 9, S. 1271 - 1281Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NF1 mutations in conjunctival melanomaIn: British Journal of Cancer (BJC) Jg. 118 (2018) Nr. 9, S. 1243 - 1247Online Volltext: dx.doi.org/ (Open Access)
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 99 (2018) S. 58 - 65Online Volltext: dx.doi.org/
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications Jg. 8 (2017) 15440Online Volltext: dx.doi.org/ (Open Access)
-
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology Jg. 30 (2017) Nr. 3, S. 350 - 356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer (EJC) Jg. 86 (2017) S. 248 - 256Online Volltext: dx.doi.org/
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 58 (2017) Nr. 9, S. 3464 - 3470Online Volltext: dx.doi.org/ (Open Access)
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology Jg. 43 (2017) Nr. 3, S. 604 - 611Online Volltext: dx.doi.org/
-
Next-Generation Sequencing to Guide Treatment of Advanced MelanomaIn: American Journal of Clinical Dermatology Jg. 18 (2017) Nr. 3, S. 303 - 310Online Volltext: dx.doi.org/
-
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsIn: European Journal of Cancer (EJC) Jg. 73 (2017) S. 61 - 70Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 22, S. 5487 - 5496Online Volltext: dx.doi.org/ (Open Access)
-
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 12, S. 2908 - 2918Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer (EJC) Jg. 67 (2016) S. 66 - 72Online Volltext: dx.doi.org/
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeIn: Science Jg. 351 (2016) Nr. 6280, S. 1463 - 1469Online Volltext: dx.doi.org/
-
Granulocytic myeloid-derived suppressor cells in peripheral blood of patients with cutaneous melanomaIn: International Immunology Jg. 28 (2016) Nr. 2, S. 99Online Volltext: dx.doi.org/
-
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma : a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 65 (2016) Nr. 8, S. 951 - 959Online Volltext: dx.doi.org/
-
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 19, S. 4848 - 4858Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT) Jg. 34 (2016) Nr. 1-2, S. 14 - 22
-
Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma) : Analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic markerIn: The American Journal of Surgical Pathology Jg. 40 (2016) Nr. 2, S. 181 - 191Online Volltext: dx.doi.org/
-
Molecular features of response to anti-PD-1 therapyIn: Chinese Clinical Oncology Jg. 5 (2016) Nr. 6, S. 74Online Volltext: dx.doi.org/ (Open Access)
-
Molekulare und immunhistochemische Diagnostik beim MelanomIn: Der Hautarzt Jg. 67 (2016) Nr. 7, S. 511 - 518Online Volltext: dx.doi.org/
-
Oncogene Status of an Interdigitating Dendritic Cell Sarcoma : Recurrent Mutations in NF1, TP53, and ARID2 Shared With MelanomaIn: The American Journal of Surgical Pathology Jg. 40 (2016) Nr. 12, S. 1721 - 1723Online Volltext: dx.doi.org/
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC) Jg. 57 (2016) S. 112 - 117Online Volltext: dx.doi.org/
-
Perspectives for immunotherapy in endocrine cancerIn: Endocrine-Related Cancer Jg. 23 (2016) Nr. 10, S. R469 - 84Online Volltext: dx.doi.org/
-
Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanomaIn: International Journal of Cancer Jg. 138 (2016) Nr. 3, S. 698 - 704Online Volltext: dx.doi.org/ (Open Access)
-
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabIn: European Journal of Cancer (EJC) Jg. 64 (2016) S. 116 - 126Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Round Table - new concept of the Arbeitsgemeinschaft Dermatologische Forschung to foster regional exchange between young clinician scientists in dermatologyIn: Experimental Dermatology Jg. 25 (2016) Nr. 10, S. 827 - 828Online Volltext: dx.doi.org/
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology Jg. 127 (2016) Nr. 3, S. 435 - 444Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Type i IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and humanIn: International Journal of Cancer Jg. 138 (2016) Nr. 8, S. 1982 - 1993Online Volltext: dx.doi.org/ (Open Access)
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature Jg. 532 (2016) Nr. 7598, S. 250 - 254Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882Online Volltext: dx.doi.org/ (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl. 2, S. 11Online Volltext: dx.doi.org/
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590Online Volltext: dx.doi.org/ (Open Access)
-
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 56 (2015) Nr. 10, S. 5854 - 5861Online Volltext: dx.doi.org/ (Open Access)
-
Future perspectives in melanoma research : meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014In: Journal of Translational Medicine Jg. 13 (2015) Nr. 1, S. 374Online Volltext: dx.doi.org/ (Open Access)
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science Jg. 350 (2015) Nr. 6257, S. 207 - 211Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Kikuchi-Fujimoto-Syndrom und adulter Morbus Still : eine seltene KoinzidenzIn: Der Hautarzt Jg. 66 (2015) Nr. 12, S. 940 - 944Online Volltext: dx.doi.org/
-
Modulation and apoptosis of neutrophil granulocytes by extracorporeal photopheresis in the treatment of chronic graft-versus-host diseaseIn: PLoS ONE Jg. 10 (2015) Nr. 8, S. e0134518Online Volltext: dx.doi.org/ (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564Online Volltext: dx.doi.org/ (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251Online Volltext: dx.doi.org/
-
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget Jg. 6 (2015) Nr. 34, S. 36041 - 36052Online Volltext: dx.doi.org/ (Open Access)
-
The Mechanism of Type I Interferon-Mediated Polarization of Tumor-Associated Neutrophils in Mice and HumanIn: Blood Jg. 126 (2015) Nr. 23,
-
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974Online Volltext: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753Online Volltext: dx.doi.org/
-
Future perspectives in melanoma research : meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013In: Journal of Translational Medicine Jg. 12 (2014) Nr. 1, S. 277Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology Jg. 27 (2014) Nr. 2, S. 175 - 183Online Volltext: dx.doi.org/
-
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research Jg. 20 (2014) Nr. 24, S. 6593 - 6604Online Volltext: dx.doi.org/
-
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma : Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cellsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 6, S. 1601 - 1609Online Volltext: dx.doi.org/
-
Open randomised prospective comparative multi-centre intervention study of patients with Cystic fibrosis and early diagnosed diabetes mellitusIn: BMC Pediatrics Jg. 14 (2014) Nr. 1, S. 70Online Volltext: dx.doi.org/ (Open Access)
-
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine Jg. 3 (2014) Nr. 5, S. 1284 - 1293Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI) Jg. 106 (2014) Nr. 9,Online Volltext: dx.doi.org/
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology Jg. 27 (2014) Nr. 4, S. 502 - 508Online Volltext: dx.doi.org/ (Open Access)
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 30, S. 3844 - 3845Online Volltext: dx.doi.org/
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332Online Volltext: dx.doi.org/
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research Jg. 19 (2013) Nr. 12, S. 3143 - 3152Online Volltext: dx.doi.org/
-
Cutting edge : an inactive chromatin configuration at the IL-10 locus in human neutrophilsIn: The Journal of Immunology (JI) Jg. 190 (2013) Nr. 5, S. 1921 - 1925Online Volltext: dx.doi.org/
-
Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancerIn: Clinical Cancer Research Jg. 19 (2013) Nr. 23, S. 6585 - 6596Online Volltext: dx.doi.org/
-
IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cellsIn: PLoS ONE Jg. 8 (2013) Nr. 2, S. e47234Online Volltext: dx.doi.org/ (Open Access)
-
Immunological consequences of selective BRAF inhibitors in malignant melanoma : Neutralization of myeloid-derived suppressor cellsIn: OncoImmunology Jg. 2 (2013) Nr. 8, e25218Online Volltext: dx.doi.org/ (Open Access)
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 952 - 952
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology Jg. 8 (2013) S. 87Online Volltext: dx.doi.org/ (Open Access)
-
Reduced frequency of CD56 dim CD16 pos natural killer cells in pediatric systemic inflammatory response syndrome/sepsis patientsIn: Pediatric Research Jg. 74 (2013) Nr. 4, S. 427 - 432Online Volltext: dx.doi.org/
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e80354Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC) Jg. 109 (2013) Nr. 2, S. 497 - 501Online Volltext: dx.doi.org/ (Open Access)
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research Jg. 73 (2013) Nr. 8 Suppl., S. 4714Online Volltext: dx.doi.org/
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer Jg. 133 (2013) Nr. 7, S. 1653 - 1663Online Volltext: dx.doi.org/
-
Gegen den Hautkrebs : Forschung zur Überwindung immuntherapeutischer Hürden beim malignen MelanomIn: Unikate: Berichte aus Forschung und Lehre (2012) Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 32 - 41Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment modelIn: Journal of Molecular Medicine Jg. 90 (2012) Nr. 2, S. 139 - 147Online Volltext: dx.doi.org/ (Open Access)
-
IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patientsIn: Cancer Immunology, Immunotherapy Jg. 61 (2012) Nr. 9, S. 1395 - 1405Online Volltext: dx.doi.org/
-
Induced and natural regulatory T cells in human cancerIn: Expert Opinion on Biological Therapy Jg. 12 (2012) Nr. 10, S. 1383 - 1397Online Volltext: dx.doi.org/
-
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samplesIn: Journal of Immunological Methods Jg. 381 (2012) Nr. 1-2, S. 14 - 22Online Volltext: dx.doi.org/
-
Phenotypic and functional characteristics of CD4⁺CD39⁺ FOXP3⁺ and CD4⁺CD39⁺FOXP3ⁿeg T-cell subsets in cancer patientsIn: European Journal of Immunology Jg. 42 (2012) Nr. 7, S. 1876 - 1885Online Volltext: dx.doi.org/
-
Dendritic cell generation and CD4+CD25HIGHFOXP3+regulatory regulatory t cells in human head and neck carcinoma during radio-chemotherapyIn: European Journal of Medical Research Jg. 16 (2011) Nr. 2, S. 57 - 62Online Volltext: dx.doi.org/ (Open Access)
-
Separation of human CD4⁺CD39⁺ T cells by magnetic beads reveals two phenotypically and functionally different subsetsIn: Journal of Immunological Methods Jg. 369 (2011) Nr. 1-2, S. 59 - 68Online Volltext: dx.doi.org/
-
Adjuvant pegylated interferon α-2b therapy for melanomaIn: Oncology Letters Jg. 1 (2010) Nr. 2, S. 237 - 241Online Volltext: dx.doi.org/
-
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology Jg. 37 (2010) Nr. 5, S. 485 - 498Online Volltext: dx.doi.org/
-
Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’In: European Journal of Cancer (EJC) Jg. 123 (2019) S. 171Online Volltext: dx.doi.org/ (Open Access)
-
EditorialIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 14 (2016) Nr. 1, S. 1 - 2Online Volltext: dx.doi.org/
-
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9570Online Volltext: dx.doi.org/ (Open Access)
-
REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 21Online Volltext: dx.doi.org/ -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 3Online Volltext: dx.doi.org/ -
Ipilimumab plus Nivolumab in Avelumab-refractory Merkel Cell Carcinoma : A retrospective multicenter AnalysisIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 47 - 48
-
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9545 - 9545Online Volltext: dx.doi.org/
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43Online Volltext: dx.doi.org/ (Open Access)
-
Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, September 30 - October 3, 2018, New York, NY,In: Cancer Immunology Research Jg. 7 (2019) Nr. 2, Supplement, S. A082Online Volltext: dx.doi.org/ -
BRAF/MEK inhibition in melanoma patients with rare BRAF mutationsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9542 - 9542Online Volltext: dx.doi.org/ (Open Access)
-
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50Online Volltext: dx.doi.org/ (Open Access) -
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8Online Volltext: dx.doi.org/ (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3036Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockadeIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3074 - 3074Online Volltext: dx.doi.org/ (Open Access)
-
The influence of extracorporeal photopheresis on NF kappa signaling and cytokine expression in lung transplant patientsIn: Transplant International Jg. 29 (2016) Nr. Suppl. 3, S. 42Online Volltext: dx.doi.org/ (Open Access)
-
Mechanistic analysis of CD3-driven T cell functions reveals a CD32a polymorphism associated with melanoma emergenceIn: Experimental Dermatology Jg. 24 (2015) Nr. 3, 42nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), March 05-07, 2015, Ulm, Germany, S. E18 - E18Online Volltext: dx.doi.org/
-
Oncogene and copy number analysis of a larger cohort of conjunctival melanomaIn: Experimental Dermatology Jg. 22 (2013) Nr. 3, S. E43
-
Quantitation of HLA-A2-MAGE3_271-279 complexes on the DC surface improves anticancer vaccine designsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 1574Online Volltext: dx.doi.org/
-
Die direkte und indirekte exogene Beeinflussung der anti-Tumorimmunität am Beispiel des Malignen MelanomsDuisburg, Essen (2014) 1 CD-ROM
-
Suppression der LPS- und Zymosan A-induzierten Immunantwort von Makrophagen durch zerstörte Muskelzellen in vitroDuisburg, Essen (2009) 2010
-
MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom : eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 28Online Volltext: dx.doi.org/ -
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity : A multicenter case series
2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) ; June 3-7, 2022, Chicago, Ill., USA and virtual,In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl.: 2022 ASCO Annual Meeting, S. 2665Online Volltext: dx.doi.org/ (Open Access)